Developing and marketing innovative vaccines and therapeutics
Emergent Biosolutions is a global specialty biopharmaceutical company developing and marketing innovative vaccines and therapeutics for certain infectious diseases, oncology and autoimmunity.
CEO Daniel J. Abdun-Nabi
Advent Contact Shahzad Malik
Advent invested in Microscience in 2001. Microscience was acquired by Emergent in 2005. Emergent listed on NYSE in November 2006 (NYSE:EBS).
Exited Investments
Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services
Press Release. ROCKVILLE, Md.--(BUSINESS WIRE)--Sept. 26, 2007--Emergent BioSolutions Inc. (NYSE:EBS), announced today that it has signed a three year contract with the U.S. Department of Health and Human Services…
Read More
